Geopolitics Alpha

Newton biotech files for bankruptcy as merger plans take shape

Published . Updated .

Key takeaways

  • Exposed: XLV, XBI, LLY, JNJ, PFE
  • Market reaction: XBI +2.1% on the day (still updating); XLV +0.0% on the day (still updating); MRK −2.7% on the day (still updating)

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.

GEOPOLITICS ALPHANewton biotech files forbankruptcy as merger plans takeshapeGEOPOLITICS ALPHA

This report is about pharma and health.

Directly affected

  • No company is named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.

  • XBI SPDR S&P Biotech ETF

    SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.

  • LLY Eli Lilly and+20.6% 30d

    Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.

  • JNJ Johnson & Johnson+0.5% 30d

    Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.

  • PFE Pfizer+9.0% 30d

    Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.

  • MRK Merck+3.3% 18d

    Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
XLV-2.95%-0.31%base+0.03%after closeafter closeafter close
XBI+1.84%+3.78%base+2.10%after closeafter closeafter close
LLY-9.22%-2.71%base+0.41%after closeafter closeafter close
JNJ-0.68%+1.70%base-1.20%after closeafter closeafter close
PFE-3.00%-2.47%base-1.34%after closeafter closeafter close
MRK-4.45%-1.43%base-2.72%after closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

Newton biotech files for bankruptcy as merger plans take shape The Business Journals

Source: The Business Journals

Price since this story was published: Select Sector Spdr Tr (XLV)

CompanyWhenMoveStatus
Johnson & Johnson (JNJ)that day-1.20%still updating
Johnson & Johnson (JNJ)three days earlier+1.70%final price
Johnson & Johnson (JNJ)five days earlier-0.68%final price
Eli Lilly (LLY)that day+0.41%still updating
Eli Lilly (LLY)three days earlier-2.71%final price
Eli Lilly (LLY)five days earlier-9.22%final price
Merck (MRK)that day-2.72%still updating
Merck (MRK)three days earlier-1.43%final price
Merck (MRK)five days earlier-4.45%final price
Pfizer (PFE)that day-1.34%still updating
Pfizer (PFE)three days earlier-2.47%final price
Pfizer (PFE)five days earlier-3.00%final price
Spdr Series Trust (XBI)that day+2.10%still updating
Spdr Series Trust (XBI)three days earlier+3.78%final price
Spdr Series Trust (XBI)five days earlier+1.84%final price
Select Sector Spdr Tr (XLV)that day+0.03%still updating
Select Sector Spdr Tr (XLV)three days earlier-0.31%final price
Select Sector Spdr Tr (XLV)five days earlier-2.95%final price

Trades by members of Congress and officials in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Select Sector Spdr Tr (XLV)

Companies mentioned with this story

  • XLV Select Sector Spdr Tr

    For “Newton biotech files for bankruptcy as merger plans take shape,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story

  • XBI Spdr Series Trust

    For “Newton biotech files for bankruptcy as merger plans take shape,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story

  • LLY Eli Lilly

    In “Newton biotech files for bankruptcy as merger plans take shape,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story

  • JNJ Johnson & Johnson

    For “Newton biotech files for bankruptcy as merger plans take shape,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story

  • PFE Pfizer

    For “Newton biotech files for bankruptcy as merger plans take shape,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story

  • MRK Merck

    Merck (MRK) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “Newton biotech files for bankruptcy as merger plans take shape.” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story

Select Sector Spdr Tr (XLV)

The 3 Nov 2026 story “Newton biotech files for bankruptcy as merger plans take shape” names Select Sector Spdr Tr (XLV) because of this story.

What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story

A second company, Spdr Series Trust (XBI), is listed for a different reason: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story

Dates in the story, and the Select Sector Spdr Tr (XLV) price range

LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1411.75.

A simple score for Select Sector Spdr Tr (XLV)

46 out of 100Price not final

“Newton biotech files for bankruptcy as merger plans take shape” scores 46 out of 100. The score uses 1 sources, and 6 linked companies. The price is not final yet.